(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
17 September 2009 (17.09.2009)

PCT

(10) International Publication Number
WO 2009/114512 A1

(51) **International Patent Classification**:
C07D 487/04 (2006.01) ***A61P 35/00*** (2006.01)
A61K 31/437 (2006.01)

(21) **International Application Number**:
PCT/US2009/036635

(22) **International Filing Date**:
10 March 2009 (10.03.2009)

(25) **Filing Language**: English

(26) **Publication Language**: English

(30) **Priority Data**:
61/035,662 11 March 2008 (11.03.2008) US
61/144,982 15 January 2009 (15.01.2009) US

(71) **Applicant** *(for all designated States except US)*: **INCYTE CORPORATION** [US/US]; Experimental Station - Building 336, Route 141 & Henry Clay Road, Wilmington, DE 19880 (US).

(72) **Inventors; and**

(75) **Inventors/Applicants** *(for US only)*: **RODGERS, James, D.** [US/US]; 2 Hillside Lane, Landenburg, PA 19350 (US). **SHEPARD, Stacey** [US/US]; 3407 Avalon Ct., Voorhees, NJ 08043 (US). **LI, Yun-Long** [US/US]; 1 Pin Oak Drive, Chadds Ford, PA 19317 (US). **ZHOU, Jiacheng** [US/US]; 46 Bay Boulevard, Newark, DE 19702 (US). **LIU, Pingli** [CN/US]; 205 Pilot Court, Newark, DE 19702 (US). **MELONI, David** [US/US]; 127 Megan Drive, Bear, DE 19701 (US). **XIA, Michael** [US/US]; 304 Clubhouse Lane, Wilmington, DE 19810 (US).

(74) **Agents**: **FREEMAN, John, W.** et al.; Fish & Richardson P.C., P.o. Box 1022, Minneapolis, MN 55440-1022 (US).

(81) **Designated States** *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) **Designated States** *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

WO 2009/114512 A1

(54) **Title**: AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS

(57) **Abstract**: The method includes the steps of performing in-vitro liver, intestinal and/or expressed enzyme assays with selected ethnobotanical substances, for both humans and a variety of animal species, to produce an array of resulting chemical entities, such as metabolites, for the human and the animals. Comparisons are then made between the chemical entities from the human in-vitro studies and the animal in-vitro studies to determine the closest match. The animal with the closest match is then used for an in-vivo study. If a match is present between the animal in-vivo results and the human in-vitro results, the matched chemical entity is isolated or synthesized and then further tested to determine the suitability of the matched chemical entity as a treatment drug.